Nasdaq

EVENITY(TM) (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was ...
Nasdaq

FDA Approves EVENITY(TM) (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of ...
Monthly Prescribing Reference

Evenity Approved to Treat Osteoporosis in Postmenopausal Women at High Risk for Fracture

The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a ...
pharmaphorum

At long last, Amgen/UCB score FDA okay for Evenity

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab) to ...
MM&M

Amgen’s innovative osteoporosis drug is something we can all get behind

Amgen recently had two big wins. First, after years of wrangling with the FDA, they finally won approval for their innovative osteoporosis drug, Evenity. Second, Amgen launched Evenity at a price ...
Yahoo Finance

Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval

Amgen, Inc. AMGN and its partner UCB announced that the FDA has approved Evenity (romosozumab-aqqg) for treating osteoporosis in postmenopausal women at high risk of fracture. Evenity is the first and ...
Yahoo Finance

Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View

Amgen Inc. AMGN and Belgian partner UCB announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a negative opinion on the marketing ...
PMLiVE

Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis

Amgen and UCB’s Evenity (romosozumab) has been recommended for use by the NHS in England and Wales by the National Institute for Health and Care Excellence (NICE). The drug can be used to treat ...
Pharmabiz

Amgen introduces Evenity in US market to treat osteoporosis in postmenopausal women at high risk for fracture

Amgen announced that Evenity (romosozumab-aqqg) is now available for shipment to wholesalers in the US. Evenity was approved by the US Food and Drug Administration (FDA) on April 9, 2019, for the ...
Reuters

Amgen sets $21,900 annual price for new Evenity bone drug

(Reuters) - Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections. The U.S. Food and Drug ...
Yahoo

Amgen sets $21,900 annual price for new Evenity bone drug

FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 file photo. REUTERS/Robert Galbraith/Files By Deena Beasley (Reuters) - Amgen Inc ...